Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.3327
+0.0127 (3.98%)
At close: Jan 30, 2026
Integrated BioPharma Revenue
Integrated BioPharma had revenue of $12.69M in the quarter ending September 30, 2025, a decrease of -6.82%. This brings the company's revenue in the last twelve months to $53.43M, up 4.72% year-over-year. In the fiscal year ending June 30, 2025, Integrated BioPharma had annual revenue of $54.35M with 8.02% growth.
Revenue (ttm)
53.43M
Revenue Growth
+4.72%
P/S Ratio
0.19
Revenue / Employee
349.18K
Employees
153
Market Cap
10.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 54.35M | 4.04M | 8.02% |
| Jun 30, 2024 | 50.32M | -355.00K | -0.70% |
| Jun 30, 2023 | 50.67M | -5.57M | -9.91% |
| Jun 30, 2022 | 56.25M | -7.31M | -11.51% |
| Jun 30, 2021 | 63.56M | 10.79M | 20.45% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Starco Brands | 47.15M |
| DAVIDsTEA | 43.33M |
| GPO Plus | 5.22M |
| BAB, Inc. | 3.29M |
| Limitless X Holdings | 1.13M |
| Glucose Health | 1.11M |
| China Foods Holdings | 422.40K |
| Strake | 223.07K |
Integrated BioPharma News
- 2 months ago - Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions - GlobeNewsWire
- 2 months ago - Integrated BioPharma GAAP EPS of $0.00, revenue of $12.69M - Seeking Alpha
- 2 months ago - Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 - Accesswire
- 4 months ago - Integrated BioPharma GAAP EPS of $0.03, revenue of $54.35M - Seeking Alpha
- 4 months ago - Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 - Accesswire
- 9 months ago - Integrated BioPharma GAAP EPS of $0.02, revenue of $13.9M - Seeking Alpha
- 9 months ago - Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 - Accesswire
- 1 year ago - Integrated BioPharma GAAP EPS of $0.00, revenue of $12.6M - Seeking Alpha